
Spruce Biosciences Investor Relations Material
Latest events

Investor Update
Spruce Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Spruce Biosciences Inc
Access all reports
Spruce Biosciences Inc. is a biopharmaceutical company developing and commercializing therapies for rare endocrine disorders. The company's leading product candidate, tildacerfont, is a non-steroidal therapy designed to improve disease control and reduce steroid dependency in patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is under clinical trial for both adult and pediatric classic CAH, as well as for females with polycystic ovary syndrome in a separateclinical trial. Spruce Biosciences has entered into strategic partnerships, including a license agreement with Eli Lilly and Company for research, development, and commercialization of compounds, and a collaboration and license agreement with Kaken Pharmaceutical for the treatment of CAH in Japan. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol SPRB.
Key slides for Spruce Biosciences Inc


Investor Update
Spruce Biosciences Inc


Corporate Presentation
Spruce Biosciences Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
SPRB
Country
🇺🇸 United States